Glimisave MV 2.2F Tablet (Glimepiride 2mg / Metformin 1000mg / Voglibose 0.2mg)

About Glimisave MV 2.2 F Tablet:

Glimisave MV 2.2 F tablet is a combination of three antidiabetic medications, used to treat type 2 diabetes mellitus. It helps to control high blood glucose levels.

Each uncoated bilayered Glimisave MV 2.2 F tablet contains Metformin Hydrochloride 1000 mg (In sustained release form), Glimepiride 2 mg, Voglibose 0.2 mg, and Excipients q.s.

Metformin is a biguanide antihyperglycaemic agent which improves glucose tolerance by lowering both basal and postprandial plasma glucose. It decreases hepatic glucose production, delays intestinal glucose absorption, and improves insulin sensitivity by enhancing peripheral glucose uptake and utilization.

Glimepiride, an antidiabeticsulphonylurea, reduces blood glucose by stimulating the insulin release from pancreatic ß-cells and decreases glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.

Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with type 2 diabetes mellitus.

Hence, the combination of Glimepiride, Metformin, and Voglibose complements each other and provides better glycemic control in the management of type 2 diabetes and probably in the prevention of its associated macrovascular and microvascular complications.

Use of Glimisave MV 2.2 F Tablet:

Glimisave MV 2.2 F tablet is prescribed for the treatment of patients with type 2 diabetes mellitus.

Related Product

Usage direction of Glimisave MV 2.2 F Tablet:

Storage direction of Glimisave MV 2.2 F Tablet:

Store protected from light and moisture, at a temperature not exceeding 30°C.